Market closedADR
Mereo BioPharma Group/$MREO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
36
Website
MREO Metrics
BasicAdvanced
$377M
-
-$0.29
0.98
-
Price and volume
Market cap
$377M
Beta
0.98
52-week high
$5.02
52-week low
$2.11
Average daily volume
1.4M
Financial strength
Current ratio
5.399
Quick ratio
5.242
Long term debt to equity
0.307
Total debt to equity
10.545
Interest coverage (TTM)
-33.37%
Management effectiveness
Return on assets (TTM)
-39.99%
Return on equity (TTM)
-77.58%
Valuation
Price to book
6.03
Price to tangible book (TTM)
6.1
Price to free cash flow (TTM)
-10.455
Growth
Earnings per share change (TTM)
30.88%
3-year earnings per share growth (CAGR)
0.18%
What the Analysts think about MREO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
MREO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MREO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MREO News
AllArticlesVideos
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
GlobeNewsWire·1 week ago
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential
MarketBeat·3 weeks ago
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $377M as of April 04, 2025.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of April 04, 2025.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.